ABSTRACT The study assessed the effect of low doses of fatty acids from fish or flaxseed oil on plasma lipid concentrations in normal humans consuming diets with either high (0.87, n = 11) or low (0.48, n = 15) dietary polyunsaturated/saturated fatty acid (P/ S) ratios. The dose of (n-3) fatty acids reflected an (n-3) intake that could easily be attained by selection of foods in a normal diet. n-3) . The flaxseed oil did not alter plasma triacylglycerol level and pro duced small changes in 20:5(n-3) and 22:6(n-3) con centrations. Total, LDL and HDL cholesterol levels were not affected by either (n-3) fatty acid. Significant differences in plasma triacylglycerol concentrations and total and LDL cholesterol levels were found be tween the two dietary P/S groups after all oil treatment periods. Levels of 18:3(n-3), 20:4(n-6), 20:5(n-3), and 22:6(n-3) in LDL were also different in high vs. low dietary P/S groups for all oil treatments and in the VLDL for the olive oil and fish oil supplementation. This study indicates that low intake of purified fish oil induces changes in plasma triacylglycerol, 20:5(n-3) levels in VLDL, LDL, and HDL, and 22:6(n-3) levels in LDL and HDL that are apparent after 3 mo and which might influence atherogenicity of lipoprotein particles in normal free-living individuals.
â€¢dietary fatty acids â€¢ plasma lipoprotein â€¢ phospholipid â€¢ cholesterol â€¢ humans Epidemiological evidence indicates that Eskimo populations consuming high levels of (n-3) fatty acids display a reduced incidence of coronary heart disease, regardless of total fat (Dyerburg et al. 1975 ) and choles terol intake (Bang et al. 1976) . Inuit adults consumẽ 4.0 g/d of eicosapentaenoic acid, whereas the average Canadian ingests less than 0.1 g/d (Holub 1988) . This finding has prompted both animal and human studies designed to assess the effects of (n-3) fatty acids that would be typical of intakes possible when consuming normal foods (reviewed by Schmidt et al. 1993, Semplicini and Valli 1994) . The (n-3) fatty acids affect meta bolic variables, including plasma triglycÃ©ride and VLDL concentrations (Saynor et al. 1988) , cellular fatty acid content, 20:4(n-6) utilization, eicosanoid balance, thromboxane A2 synthesis, platelet aggregation (Weber and Leaf 1991) , and cell-lipoprotein interactions (Fox and DiCorelto 1988 , Hostmark et al. 1988 , Shimokawa and Vanhoutte 1989 .
Generally, normal individuals fed marine (n-3) fatty acids demonstrate a reduction in plasma triacylglycerol and VLDL levels. These effects are dose dependent (Si mons et al. 1985) and reversible (Goodnight et al. 1982) . A variety of mechanisms have been suggested to ex plain the hypotriacylglyceridemic effect of (n-3) fatty acids (Harris 1989 , Lang and Davis 1990 , Rustan and Drevon 1989 , Rustan et al. 1988 , Sanders 1991 .
Although the effect of 18:3(n-3), 20:5(n-3), and 22:6(n-3) on plasma cholesterol levels is debatable, in-dividuals fed large amounts of marine fish display re ductions in LDL cholesterol (Connor 1988) . These re sults are due to changes in diet and increases in the polyunsaturated/saturated fatty acid (P/S)ratio, but the results fail to accurately reflect the specific effects of (n-3) fatty acids on serum lipid levels.
Animal studies indicate that the efficacy of (n-3) fatty acids in lowering plasma triacylglycerol, choles terol levels and arachidonate levels depends on the rela tive amounts of linoleic acid and saturated fatty acids in the diet (Garg et al. 1988 (Garg et al. , 1989a (Garg et al. and 1989b . Because the attributes of (n-3) fatty acids are limited to the longer-chain forms, it is important that conversion of 18:3(n-3) to 20:5(n-3) and 22:6(n-3) occur. In rats, the conversion of 18:3(n-3) to 20:5(n-3) and the inhibition of conversion of 18:2(n-6)to 20:4(n-6) is maximized by partial replacement of dietary 18:2(n-6)with saturated fatty acids (Garg et al. 1989a ). This suggests that (n-3) fatty acid supplementation for humans may be more effective when the dietary P/S ratio is low. This hy pothesis deserves investigation because many Canadi ans normally consume diets with a lower P/S ratio.
To date, the effects of (n-3) fatty acids have been assessed in a variety of short-term placebo-controlled or long-term uncontrolled studies (reviewed by Schmidt et al. 1993) . However, the effect of low doses of (n-3) fatty acids on quantitative pool sizes of plasma lipoprotein fatty acids has not been assessed in a longerterm (>30 d), randomized, double-blind controlled crossover design. The objective of this study is to deter mine the long-term effects of purified (n-3) fatty acids on plasma triacylglycerol, cholesterol and lipoprotein fatty acid content in normal individuals. The effect of 18:3(n-3)vs. 20:5(n-3) and 22:6(n-3) was assessed by providing a purified flaxseed or fish oil supplement to individuals who normally consume a low P/S ratio diet compared with individuals who normally consume a higher P/S ratio diet.
MATERIALS AND METHODS
Purified oils. Chromatographically pure triglycÃ©r ides of olive oil, flaxseed oil and fish oil were provided by Lipidteknik, Stockholm, Sweden. These oils were prepared by commercial-scale physical and Chromato graphie fractionation procedures to prepare a triglycÃ©r ide fraction free of other polar or nonpolar lipids, perox ides and hydroperoxides that characterize many com mercially available fish oils. Major fatty acid constituents of the purified oils were analyzed and are illustrated (Table 1) . Artificial vanilla extract was added at a concentration of 0.05 g/100 g of olive oil and 0.2 g/100 g of flaxseed and fish oils to blind participants to the type of oil treatment. Flavored oils were encapsu lated in 0.5-g capsules under nitrogen by Banner Gela tin (Olds, Alberta, Canada) and stored in nitrogen- (n-6)18:3 (n-3)20:020:2 (n-6)20:3 (n-9)20:4 (n-6|20:5 (n-3)22:4 |n-6)22:5 (n-6)22:5 (n-3)22:6 [n-3)0.216.10.11.52.662.713.00.90.1â€"â€"â€"â€"â€"â€"â€"â€"9.616.68.90.22.314.
1 Oils were flavored with artificial vanilla extract and encapsu lated in 0.5-g capsules.
2 The fatty acid composition was determined by gas liquid chromatography using fused silica capillary columns.
flushed brown bottles at -20Â°C.Participants were in structed to store oil capsules in the freezer. Peroxide analysis was performed every 1-2 mo to ensure that there was no increase in oil peroxide level over the course of the study (Turini et al. 1991) .
Participants and experimental design. The study protocol was approved by the Human Ethics Review Committees of the Faculty of Home Economics and the Faculty of Medicine, University of Alberta, Canada. Participants were recruited through advertisements posted at the University of Alberta campus. An initial visit was arranged to outline the project, review partici pant responsibilities and obtain informed written con sent. Free-living individuals were instructed to docu ment all food and drink consumed on a daily basis for a period of 7 d. This record was taken over 1 wk to establish normal dietary patterns and was repeated at 3-mo intervals (total of five dietary records of 7 d each). Dietary intakes were calculated using a nutritional da tabase derived from the nutrient data bank set up within the computer system at the University of Al berta. The values used were based on Nutritional Val ues of Some Common Foods (1988) and revised to in clude an updated fatty acid composition of foods. Parti cipants were grouped into higher or lower P/S groups based on this analysis.
The physical, dietary and clinical characteristics of participants in the low and high P/S groups are illus trated ( Table 2) . Percentage of ideal body mass was cal culated using Metropolitan Life Insurance Company tables (1983)and fell within normal ranges for all parti- 1Values are means Â±so of base-line measurements. 2 Within a row, values without a common superscript are signifi cantly different [P < 0.05). Significant differences between high and low P/S subjects were determined by a two tailed t test.
3 Polyunsaturated/saturated fatty acid ratio. 4 Normal ranges for clinical data according to University of Al berta Hospitals standards are given in parentheses.
5 Glycosylated hemoglobin.
cipants throughout the study. The participants were free from any known metabolic diseases and were not on any drug therapy. Initially, 32 individuals were re cruited into the study, with 16 participants in each dietary group. The low P/S group consisted of individu als with a dietary P/S ratio of 0.74 or less (range of 0.25 to 0.74), while the high P/S participants had a minimum P/S ratio of 0.43 when assessed by the two dietary records (range of 0.43 to 1.52).
Final analyses were based on results from 15 partici pants consuming low P/S diets and 11 participants con suming high P/S diets. These 26 subjects exhibited con sistent intakes of fat, protein and carbohydrate ex pressed on a % energy basis (not significantly different for the five dietary records collected). Of the initial 32 participants, one individual was unable to comply with the oil supplement protocol, and five of the remaining participants were not included in the final data analysis because they altered their fat intake and did not remain within their initial dietary P/S group. Participant com pliance was based on regular contact and on counts of returned oil capsules. Compliance was also evident in plasma fatty acid changes. Initial fasting blood samples were drawn at the Metabolic Day Care Centre, Univer sity of Alberta Hospitals, to ensure that participants had normal lipid profiles and were free of metabolic complications.
Participants were counseled at this time and throughout the study to keep within their usual fat intake level and P/S grouping. A follow-up phone call was made approximately once a month to reinforce advice, assess compliance and answer any questions.
A controlled, randomized, double-blind crossover study design was used in this study. All participants were initially supplemented with olive oil (placebo) for a period of 3 mo and were instructed to consume the same number of olive oil capsules that they would con sume during the flaxseed oil treatment period. The dose of olive oil during this period was~35 mg 18:l/(kg body weight â€¢ d). Blood samples and diet records were collected and analyzed at 0, 3, 6 and 9 mo. Following the placebo phase, participants were randomly assigned to either flaxseed oil or fish oil for 3 mo and finally crossed over to the alternative (n-3) fatty acid treatment for the last 3 mo. Throughout the experiment, treat ment refers to either the fish oil or flaxseed oil [(n-3) fatty acid] treatment. Flaxseed oil was supplemented at a dose of 35 mg of 18:3(n-3)/(kg body weight â€¢ d) and fish oil at a dose of 35 mg of 20:5(n-3) and 22:6(n-3) (total combined)/(kg body weight-d). For example, for a 70-kg subject, the oil supplementation level would be~4.3 g/d for flaxseed and olive oils and~7 g/d for fish oil. This (n-3) intake could be achieved while con suming a normal diet by selection of appropriate foods.
Plasma and biochemical analysis. All plasma and biochemical analyses were done by investigators who were unaware of the treatment group. Blood samples were drawn into tubes containing disodium EDTA after participants fasted for 12-14 h. Cholesterol and triacylglycerol concentrations were determined using triglycÃ©ridesand cholesterol determination kits manu factured by BMC (Boehringer Mauhein, Laval, QuÃ©bec, Canada) on a Hitachii 911 Analyzer (Boehringer Mau hein, Laval, QuÃ©bec, Canada). The enzymatic methods used for the assays are as described in the literature (Allain et al. 1974, Buccio and David 1973) . Plasma lipoprotein fractions (VLDL, LDL and HDL) were sepa rated by sequential ultracentrifugation at 356, 160 x g and 20Â°Cin a Beckman TLA-100.2 angle head rotor (Beckman Instruments, Palo Alto, Ã ‡A) (Clandinin et al. 1995) . VLDL, the upper layer with a density range of 0.96-1.006 kg/L after ultracentrifugation for 3 h, was removed by micropipetting. To the remaining sample, 1.3199 kg/L solution was added ata volume ratio of 1:5, and the solution was mixed well. This was followed by layering on top with 1.063 kg/L NaBr solution. The sample was ultracentrifuged for 4 h, and the top LDL layer was removed. HDL isolation followed a similar process, with the exception that 7.593 mol/L NaBr so-lution (v/v 1:2) was added to adjust the density of the solution, and the mix was layered with 2.973 mol/L NaBr solution. The samples were ultracentrifuged for 6 h. LDL and HDL samples were placed in dialysis tubing into 0.196 mol/L NaCl overnight at 4Â°Cto re move any extraneous density gradient that may have been taken up with the sample. The purity of the lipoprotein fractions separated was checked by electrophoresis to ensure that fractions were not cross-contami nated (Nobel 1968) .
Lipoprotein lipids were extracted by a modified Folch method (Folch et al. 1957 ) using chloroform/ methanol (2:1 v/v) solution containing 0.05% (v/v) ethoxyquin as an antioxidant. Phospholipid, triacylglycerol and cholesteryl ester fractions were separated on silica G plates (Analtech, Newark, DE) using a sol vent system of petroleum ether/diethyl ether/glacial acetic acid 80:20:1 (v/v/v). Triacylglycerol and cholest eryl ester fractions were saponified with 0.5 mol/L methanolic KOH in a 110Â°Csand bath for 60 and 90 min, respectively. Following saponification, samples were methylated with 14 g/100 g boron trifluoride in methanol and hexane (Morrison and Smith 1964) . Tri glycÃ©ridesupplements were methylated with boron tri fluoride. A known amount of standard (tripentadecanoin and cholesteryl pentadecanoate) was added to the lipid extract prior to thin layer chromatography for quantification of the fatty acid content of the triacylglycerol and cholesteryl ester fractions. Heptadecanoic acid was added prior to methylation for quantification of the fatty acid content of the phospholipid fraction. All samples were stored at -70Â°C.
Fatty acid methyl esters were separated and quantitated by automated gas liquid chromatography using a BP20 capillary column (Supelco Canada, Mississauga, Ontario) (Hargreaves and Clandinin 1987) . Peaks for fatty acid methyl esters were identified by comparison with authentic compounds and standards (PUFA 1 and 2, Bacterial Methester MIX CP, GLC MIXES 10 to 100 and methylester MIX-14) purchased from Supelco Can ada and Sigma Chemical (St. Louis, MO) and with known samples of biological source (MaxEPA oil) as described earlier (Hargreaves and Clandinin 1987) . These GLC operating conditions separate methyl esters of all saturated, cis-monounsaturated, and ci's-polyunsaturated fatty acids from 14 to 24 carbons in chain length. Statistical analysis. Food intake records were com pared by repeated measures ANOVA (SAS Inc., Gary, NC). The effects of (n-3) fatty acids on plasma triacylglycerol, total, LDL and HDL cholesterol levels, and lipoprotein fatty acid levels were assessed by repeated measures ANOVA procedures. Significant differences between treatments were determined by Duncan's multiple range test (Steel and Torrie 1980) . Statistical significance was set at P < 0.05. Significant overall group effects were tested for plasma triacylglycerol and total, LDL and HDL cholesterol by two-way ANOVA (diet P/S group, oil treatment) and in plasma lipopro tein fatty acids by three-way ANOVA (diet P/S group, oil treatment, lipoprotein fraction). To test if (n-3) fatty acid treatments lowered plasma triacylglycerol, choles terol and 20:4(n-6) levels, and increased 20:5(n-3) and 22:6(n-3) levels to a greater extent in participants con suming low P/S diets than in participants consuming high P/S diets, changes in these parameters were com pared by ANOVA. In this analysis, the order of treat ment and time elapsed from the placebo period was also considered. Changes in plasma triacylglycerol, cholesterol and lipoprotein fatty acids were also calcu lated and compared by subtracting placebo (olive oil) values from (n-3) fatty acid treatment values. Signifi cant differences in lipid changes between high P/S par ticipants and low P/S participants were determined by two-way ANOVA (diet P/S group, oil treatment) for plasma triacylglycerol and total, LDL and HDL choles terol, and three-way ANOVA (diet P/S group, oil treat ment, lipoprotein fraction) for plasma lipoprotein fatty acids.
RESULTS
Participants' weights and dietary intakes did not dif fer significantly among the three oil treatment phases and were therefore considered to be consistent through out the study. Significant dietary differences between the high and low P/S groups were evident in carbohy drate and saturated fatty acid intakes only (Table 2) . Initial blood samples indicated that plasma triacylglyc erol, total, LDL, and HDL cholesterol, glucose, glycosylated hemoglobin, insulin, C-peptide, and glucagon fell within normal ranges for all participants and re mained normal during (n-3) fatty acid supplementation. Base-line LDL cholesterol concentration, the only clin ical variable that differed significantly between the two dietary groups, was lower in the high P/S group. Effect of (n-3) fatty acids on plasma triacylglycerol and lipoprotein cholesterol levels. Plasma triacylglycerides were significantly reduced by the fish oil treat ment in the low P/S group (Table 3) . The flaxseed oil treatment did not reduce triacylglycerol levels in either dietary group. Plasma total, LDL and HDL cholesterol were not significantly affected by dietary supplementa tion with fish or flaxseed oils in either P/S group.
Plasma lipoprotein fatty acid concentrations. Tria cylglycerol. Fish oil significantly increased 20:5(n-3) and 22:6(n-3) in VLDL and LDL fractions for both P/S groups (Table 4 ). In the HDL fraction, 20:5(n-3) and 22:6(n-3) levels were also elevated in the HDL fraction of participants with high dietary P/S intakes. In the low dietary P/S group, only 20:5(n-3) HDL was in creased (Table 4 ). The level of 20:4(n-6) was elevated only in LDL particles for participants consuming a low P/S diet. Participants consuming high P/S diets dis- 1Values are means Â±SE, n = 15 and n = 11 for low and high P/S groups, respectively. Significant oil treatment effects were determined by repeated measures ANOVA. Within a row values without a common superscript are significantly different (P < 0.05|.
2 Abbreviations used: P/S, polyunsaturated/saturated fatty acid ratio; TG, triacylglycerol; TC, total cholesterol.
played no change in 20:4(n-6) levels, reduced 18:1 and elevated 18:3(n-3) levels in LDL. Fish oil supplementa tion lowered 16:0, 18:0 and 18:1 in the HDL of the high P/S group and 16:0 and 18:0 in the HDL of the low P/S group. Flaxseed oil supplementation significantly increased 20:5(n-3) levels in the HDL triacylglycerol of participants consuming high P/S ratio diets (Table 4) . The flaxseed oil treatment did not affect 20:5jn-3) or 22:6(n-3) levels/ however, 20:4(n-6) was increased sig nificantly in the HDL triacylglycerol fraction of partici pants consuming a low P/S diet. Flaxseed oil supple mentation increased triacylglycerol 18:3(n-3) levels in all participant lipoproteins, with the exception of the HDL triacylglycerol fraction for participants consum ing a high P/S diet. The low P/S group displayed an elevation in VLDL 14:0 and a reduction in HDL 18:0.
Cholesteryl ester. The fish oil treatment increased 20:5(n-3) levels in all lipoproteins of both dietary P/S groups (Table 5) . Substantial incorporation of 20:5(n-3) into the cholesteryl ester fraction confirmed partici pant compliance to fish oil supplements (Glatz et al. 1989) . Lipoprotein 22:6(n-3) levels were elevated in the LDL and HDL fractions of both dietary groups (Table  5) . Fish oil supplementation did not significantly alter the 20:4(n-6) concentration of any lipoprotein. The level of 18:3(n-3) was elevated in the LDL fraction of participants in the low P/S group and the HDL fraction of participants in the high P/S group. Fish oil reduced 14:0, 16:0; 18:0 and 18:1 in the VLDL of participants consuming a low P/S diet. Participants consuming high P/S diets displayed reduced VLDL 14:0 and 18:0 and elevated HDL 18:0.
Flaxseed oil supplementation increased 20:5(n-3) levels only in the VLDL cholesteryl ester fraction of participants consuming high P/S diets (Table 5) . Levels of 22:6(n-3) and 20:4(n-6) were not significantly af fected. Participants supplemented with flaxseed oil dis played increased 18:3(n-3) levels in the VLDL particles of participants consuming a high P/S diet and in the LDL particles of participants in both dietary P/S groups. In low P/S participants, flaxseed oil reduced the VLDL 14:0 and decreased 18:0 in all lipoproteins.
Phospholipid. In both dietary P/S groups, fish oil increased 20:5(n-3) in all lipoproteins (Table 6 ). The level of 22:6(n-3) was also elevated in the LDL and HDL of both P/S groups (Table 6 ), and 18:3(n-3) was elevated in the LDL fraction of participants consuming a high P/ S diet and the HDL fraction of participants consuming a low P/S diet. In both dietary P/S groups, LDL 14:0 and 18:0 levels increased, and VLDL 18:1 level was reduced.
Participants consuming high P/S ratio diets supple mented with flaxseed oil displayed increased 20:5(n-3) levels only in the VLDL fraction (Table 6 ). Levels of 22:6(n-3) and 20:4(n-6) were not significantly affected. The flaxseed oil treatment elevated 18:3(n-3) in all lipo proteins and both dietary P/S groups.
DISCUSSION
Low doses of fish oil significantly reduced plasma triacylglycerol concentrations in participants with low intakes of polyunsaturated to saturated fatty acids. This suggests that, in normal free-living individuals consuming a typical North American diet, the hypotriacylglyceridemic effects of marine (n-3) fatty acids may be sustained for 3 mo, particularly in those consuming a diet relatively high in saturated fats, e.g., dairy fats. Short-term studies (Bronsggeest-Schoute et al. 1981 , Sanders and Roshanai 1983 , Sztern and Harris 1991 confirm this finding. Participants in the present study demonstrated 24-27% reductions in triacylglycerol levels after 3 mo of fish oil treatment, and this finding 9610.281.6618.757.410.830.580.200.181.52b0.1832.261.250.12 0.04b0.918.571.9818.576.520.590.450.320.131. 0.05X 1 Values are means Â±SE,n = 15 for low and n = 11 for high P/S groups of subjects. Significant oil treatment effects were determined by repeated measures ANOVA. abcjndicate oil treatment effects within subjects in the low dietary P/S group (P < 0.05). xyzmdicate oil treatment effects within subjects in the high dietary P/S group (P < 0.05).
is confirmed by other studies (Blonk et al. 1990 , Sanders et al. 1989 , Schmidt et al. 1993 .
The lack of a fiaxseed oil effect on triacylglycerol levels has been observed by others (Sanders and Roshanai 1983) , and it suggests that 20:5(n-3) and 22:6(n-3) are responsible for the hypotriglyceridemic effect. The results of the present study suggest that either the flaxseed oil intake was not great enough to produce sufficient amounts of long-chain (n-3) fatty acids (Ta bles 4 and 5) or the conversion of 18:3(n-3) to 20:5(n-3) was limited, even in participants consuming a low P/S diet. This limitation in conversion of 18:3(n-3) to 20:5(n-3) was apparent in the changes in fatty acid concentration of the lipoproteins after each oil treat ment (Fig. 1, 2) . Although the flaxseed treatment ele vated 18:3(n-3) levels of lipoprotein fractions more than the fish oil treatment (Fig. 1) , no changes oc curred in the 20:5(n-3) levels when consuming flaxseed oil (Fig. 2) .
Plasma total and LDL cholesterol levels were slightly (P < 0.1) but not significantly elevated by fish oil and flaxseed oil supplements in participants in both dietary P/S groups. Other investigators (Brown et al. 1990 ) have reported similar increases in plasma total and LDL cholesterol levels when humans were supple mented with lower doses (1.5-2.0 g/d) of marine (n-3) fatty acids for shorter periods of feeding. In contrast, some researchers (Illingworth et al. 1984) report that ten-fold higher doses (24 g/d) of 20:5(n-3) and 22:6(n-3) reduce total and LDL cholesterol levels. Studies that Values are means Â±SE,n = 15 for low and n = 11 for high P/S groups of subjects. Significant oil treatment effects were determined by repeated measures ANOVA. abcjndicate oil treatment effects within subjects in the low dietary P/S group (P < 0.05).^Indicate oil treatment effects within subjects in the high dietary P/S group |P < 0.05).
used large doses of marine oil supplements may be test ing the effect of a change in fat quality and P/S ratio rather than the specific effects of (n-3) fatty acids. The relative amounts of 20:5(n-3) and 22:6(n-3) in fish oil preparations may also influence the net change in plasma lipids and lipoprotein cholesterol levels ob served (Childs et al. 1990) .
Although the lipid hypothesis focuses on reducing total and LDL cholesterol levels, plasma triacylglycerol may also be a predictor of coronary heart disease (Aus tin 1991). Therefore, reductions in plasma triacylglyc erol may also promote a less atherogenic plasma lipid profile (Assmann et al. 1991) . The present study dem onstrates that low doses of fish oil, easily within the range of normal intakes, reduce plasma triacylglycerol levels without significantly affecting total and LDL cholesterol levels.
Fish oil-induced fatty acid changes in plasma lipoproteins may alter in vivo LDL oxidation and reduce atherogenic potential (Simopoulos 1991) . In rabbits fed 300 mg/(kg body weight-d) of purified eicospentaenoate, LDL particles were less susceptible to oxidative modification by Cu2+ than the LDL of control rabbits (Saito et al. 1991) . The incorporation of 20:5(n-3) and 22:6(n-3) into LDL cholesterol ester may also increase lipoprotein core fluidity and reduce the particle atherogenicity (Harris 1989) . These studies suggest ways in which a change in fatty acid composition of the lipopro tein particle may also be important in determining atherogenicity of lipoprotein particles present. 1 Values are means Â±SE,n = 15 for low and n = 11 for high P/S groups of subjects. Significant oil treatment effects were determined by repeated measures ANOVA. abcjndicate oil treatment effects within subjects in the low dietary P/S group (P < 0.05). xyzjndicate oil treatment effects within subjects in the high dietary P/S group [P < 0.05).
Participants
consuming a low P/S diet, supple mented with fish oil, displayed a significant increase in 20:4(n-6) levels in LDL triacylglycerol. Arachidonic acid levels in all other lipoprotein lipid classes were not significantly affected by the fish oil treatment. Similar results were reported when low (DeLany et al. 1990) and moderate doses of long-chain (n-3) fatty acids were consumed by normal individuals (Bronsggeest-Schoute et al. 1981) . However, when the (n-3) fatty acid dose was increased to 8 g/d, 20:4(n-6) levels were signifi cantly reduced (DeLany et al. 1990) . In cases in which high levels of (n-3) fatty acids are supplemented, it is unclear whether the observed reduction in 20:4(n-6) is a result of the dietary substitution of (n-3) fatty acids for 20:4(n-6) or is an effect of the (n-3) fatty acid. In the present study, 20:4(n-6) levels were in general not significantly altered, indicating that the hypotriacylglyceridemic effect may be specifically attributed to the (n-3) fatty acids supplemented.
Flaxseed oil treatment significantly increased 20:5(n-3) levels in the HDL triacylglycerol, VLDL phospholipid and VLDL cholesteryl ester fractions of parti cipants consuming a high P/S diet, suggesting that some desaturation and elongation of 18:3(n-3) occurred. The dose of flaxseed oil may have been inadequate to compete for A6-desaturation, even in the low dietary P/S group. Others (Sanders and Roshanai 1983 ) have failed to demonstrate significant increases in 20:5(n-3) when participants were fed 9 g/d of 18:3(n-3), and they suggest that human conversion of 18:3(n-3) to 20:5(n- I Effect of (n-3) fatty acid treatments on change in 18:3(n-3) in plasma lipoproteins of subjects receiving fish or flaxseed oil treatments. Values reported are means Â±SE (n = 26) of differences in fatty acid levels between olive oil and (n-3) fatty acid treatments. "Indicates significant effect of oil treatment (P < 0.05). L and H indicate low and high dietary polyunsaturated/saturated fatty acid ratio (P/S) groups, respectively.
3) is limited, whereas the 18:2(n-6) to 20:4(n-6) pathway is more efficient. This theory was recently challenged by Emken et al. (1993) , who found that high dietary levels (30 g/d vs. 15 g/d) of 18:2(n-6) did not influence desaturation of 18:3(n-3) or incorporation of 18:3(n-3) into plasma lipids. These researchers found that the conversion of 18:3(n-3) was three to four times greater than the conversion of 18:2(n-6); however, the total amount of 18:3(n-3) metabolites produced from 3.5 g/ d of 18:3(n-3) was very low (0.35 g/d), and a significantly larger dose of 18:3(n-3) (21-29 g/d) might be required to provide the equivalent effects of 2-2.5 g/d of marine (n-3) fatty acids.
It was hypothesized that plasma lipid and lipoprotein parameters would be affected more by a (n-3) fatty acid treatment in individuals consuming low P/S ratio diets than in individuals consuming high P/S ratio diets. This hypothesis was based on the rationale that lower levels of the linoleate metabolite, 20:4(n-6), would compete less with fish oil for incorporation into plasma lipid and lipoprotein fractions. In this regard, plasma triacylglycerol levels were significantly re duced in the low P/S group but not significantly re duced in the high P/S group. Although it was hypothe sized that the conversion of 18:3(n-3) to 20:5(n-3) would be more efficacious in the low P/S group, this was not observed.
Presently, many human studies rely on dietary macronutrient analysis but do not account for specific di etary fatty acids, for example, arachidonate. This may be important when fish oil is supplemented in low doses because small changes in dietary arachidonate may influence the (n-3) fatty acid effect, particularly when the subject's intake of (n-3) fatty acids from ma rine sources is low.
It is apparent that modest intake of marine (n-3) fatty acids promotes change in lipoprotein fatty acid con tent, which may affect a variety of physiological events associated with atherosclerosis. Cellular events such as reductions in fibrinogen (Hostmark et al. 1988 ), platelet activating factor (Sperling et al. 1987 ), platelet-derived growth factor (Fox and DiCorelto 1988) , and increases in tissue plasminogen activator and endothelial-derived relaxation factor (Shimokawa and Vanhoutte 1989) have been induced by fish oil supplementation and may augment the cardiovascular benefits of 20:5(n-3) and 22:6(n-3). It is important for future studies to assess the effects of (n-3)fatty acids with regard to lipoprotein composition, eicosanoid production, platelet aggregation, lipid-dependent enzymes, endothelial and smooth muscle cell interactions, and other factors in volved in the atherogenic process in relation to the intake of specific dietary saturated fats currently per ceived to influence the atherosclerotic process.
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